Reference health
Luseogliflozin inhibits high glucose-induced TGF- <b>β</b> 2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
39/39 checkable references clean · checked 2026-08-10
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 39 checked references that resolve
resolves10.2337/diacare.27.3.699
Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes
resolves10.1016/j.ejheart.2005.01.017
Influence of Diabetes on the sUrvival Of Patients Hospitalized with Heart Failure: A 12-Year Study
resolves10.3389/fphys.2020.603247
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
resolves10.1089/rej.2015.1738
Protective Role of Sodium–Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes
resolves10.1002/dmrr.3327
Albuminuria‐lowering effect of sodium‐glucose cotransporter 2 inhibitors could be partly attributable to the attenuation of tubular damage in type 2 diabetic patients
resolves10.2337/db16-0733
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
resolves10.1186/s12933-019-0816-2
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
resolves10.1042/CS20190585
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
resolves10.1161/JAHA.119.013389
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
resolves10.1007/s00125-007-0628-x
Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto–Kakizaki rat model of type 2 diabetes: critical role of Akt
resolves10.1007/s00125-016-4134-x
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
resolves10.1007/s00125-017-4509-7
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
resolves10.1177/1479164121999034
Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2
resolves10.1155/2017/8503754
<i>db</i>/<i>db</i>Mice Exhibit Features of Human Type 2 Diabetes That Are Not Present in Weight-Matched C57BL/6J Mice Fed a Western Diet
resolves10.1161/01.CIR.0000093277.20968.C7
Cariporide (HOE642), a Selective Na
<sup>+</sup>
-H
<sup>+</sup>
Exchange Inhibitor, Inhibits the Mitochondrial Death Pathway
resolves10.1371/journal.pone.0168255
GSK-3β/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy
resolves10.1007/s12325-014-0102-3
Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
resolves10.1016/j.jphs.2016.02.003
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
resolves10.1159/000356673
High Glucose Concentration Stimulates NHE-1 Activity in Distal Nephron Cells: the Role of the Mek/Erk1/2/p90<sup>RSK</sup>and p38MAPK Signaling Pathways
resolves10.1111/bph.15193
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
resolves10.1186/s12933-019-0947-5
Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
resolves10.1016/j.bbrc.2015.10.109
Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice
resolves10.1210/en.2018-00336
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
resolves10.1016/j.cardiores.2004.01.021
Calcineurin?NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs
resolves10.1161/01.RES.64.5.937
Nonsynchronous accumulation of alpha-skeletal actin and beta-myosin heavy chain mRNAs during early stages of pressure-overload--induced cardiac hypertrophy demonstrated by in situ hybridization.
resolves10.1016/j.yjmcc.2010.10.033
Transforming growth factor (TGF)-β signaling in cardiac remodeling
resolves10.1016/S0002-8703(97)70245-X
Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study
resolves10.3389/fphys.2016.00462
Exercise Attenuates Intermittent Hypoxia-Induced Cardiac Fibrosis Associated with Sodium-Hydrogen Exchanger-1 in Rats
resolves10.1016/S0092-8674(00)81573-1
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
resolves10.1161/CIRCRESAHA.108.175141
Activation of Na
<sup>+</sup>
/H
<sup>+</sup>
Exchanger 1 Is Sufficient to Generate Ca
<sup>2+</sup>
Signals That Induce Cardiac Hypertrophy and Heart Failure
resolves10.1111/j.1747-0285.2006.00360.x
A Cell‐permeable NFAT Inhibitor Peptide Prevents Pressure‐Overload Cardiac Hypertrophy
resolves10.1161/01.ATV.0000225286.30710.af
Therapeutic Potential of a Synthetic Peptide Inhibitor of Nuclear Factor of Activated T Cells as Antirestenotic Agent
resolves10.1136/bmjdrc-2020-001303
Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic <i>db/db</i> mice
resolves10.1038/srep26428
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
resolves10.1016/j.metabol.2015.10.010
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
resolves10.1371/journal.pone.0100777
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
resolves10.1016/j.ahj.2011.07.030
Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis
The 1 reference without a DOI — listed, not checked
no DOI — not checkedCommittee for the Update of the Guide for the Care and Use of Laboratory Animals.
Guide for the Care and Use of Laboratory Animals
. 8th ed. Washington (DC): National Academies Press (US), 2011, pp1–220.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1177/03000605221097490"><img src="https://citestamp.com/citestamped/10.1177/03000605221097490/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1177/03000605221097490)